Nuvo Research® announces 2014 second quarter results
PR Newswire - Wed Jul 30, 4:00PM CDT
Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced its financial and operational results for the second quarter ended June 30, 2014.
IGI Laboratories, Inc. Announces Joint Stipulation
PR Newswire - Thu Jun 26, 7:30AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced that it has entered into an agreement with Mallinckrodt LLC, Mallinckrodt Inc., and Nuvo Research, Inc. (TSX: NRI) (together Mallickrodt) to settle a declaratory judgment action brought by IGI, concerning IGI's filing of an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w. Under the terms of this agreement, Mallinckrodt granted IGI a non-exclusive license to launch its diclofenac sodium topical solution 1.5% product on March 28, 2015. IGI received tentative approval of its diclofenac sodium topical solution 1.5% from the FDA on May 7, 2014.
Nuvo Research to present at Bloom Burton & Co Healthcare Investor Conference
CNW Group - Tue Jun 17, 11:30AM CDT
Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced that John London, the Company's President and Co-Chief Executive Officer will be providing a corporate update at the Bloom Burton & Co Healthcare Conference on Wednesday, June 18, 2014 in Toronto.
Nuvo Research announces director election results of its annual general meeting
PR Newswire - Wed Jun 11, 2:30PM CDT
Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced that at its 2014 Annual and Special Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated April 30, 2014 were elected as directors of the Company.
Nuvo Research® announces U.S. FDA approval of third-party generic of PENNSAID 1.5%
CNW Group - Thu May 29, 7:00AM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced that a third party has received U.S. Food and Drug Administration (FDA) approval to market and sell a topical diclofenac sodium 1.5% solution in the United States. The product is a generic version of Nuvo's PENNSAID (diclofenac sodium topical solution) 1.5% w/w (PENNSAID 1.5%).
Nuvo Research® closes $3.1 million private placement
CNW Group - Tue Apr 01, 6:30AM CDT
Nuvo Research Inc. (TSX:NRI), (the "Company"
Nuvo Research announces 2013 fourth quarter & year-end results
CNW Group - Thu Feb 20, 4:00PM CST
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced its financial and operational results for the fourth quarter and year ended December 31, 2013.
Nuvo Research Announces the U.S. Commercial Launch of PENNSAID® 2% by Mallinckrodt
CNW Group - Mon Feb 10, 7:00AM CST
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced the U.S. commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) by its U.S. commercial licensee Mallinckrodt (NYSE:MNK). PENNSAID 2% is the first twice per day topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the United States for the treatment of the pain of osteoarthritis of the knee(s). Nuvo receives royalties on U.S. sales of PENNSAID 2%.
Chrysler Group Reports Full-Year 2013 Net Income of $2.8 Billion, Including a $962 Million Non-Cash Tax Benefit
PR Newswire - Wed Jan 29, 4:26AM CST
-- Chrysler Group LLC's full-year net income was $2.8 billion, including a $962 million non-cash tax benefit related to the release of valuation allowances on deferred tax assets; full-year 2012 net income was $1.7 billion
Nuvo Research Announces FDA Approval of PENNSAID® 2%
CNW Group - Fri Jan 17, 6:00AM CST
- Mallinckrodt to Launch PENNSAID 2% in the U.S. in Q1 2014 -
Nuvo Research(R) and NovaMedica Sign Agreement to Market Pennsaid(R) in Russia
Business Wire - Thu Dec 19, 6:30AM CST
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology, and NovaMedica LLC (NovaMedica), a Russian pharmaceutical company, today announced that they have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo's Pennsaid 1.5% and Pennsaid 2% products in Russia and some of the Community of Independent States (CIS).
Nuvo Research® and NovaMedica sign agreement to market Pennsaid® in Russia
CNW Group - Thu Dec 19, 6:30AM CST
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology, and NovaMedica LLC (NovaMedica), a Russian pharmaceutical company, today announced that they have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo's Pennsaid 1.5% and Pennsaid 2% products in Russia and some of the Community of Independent States (CIS).